EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
11.63
+0.08 (0.69%)
At close: Oct 17, 2025, 4:00 PM EDT
11.58
-0.05 (-0.43%)
After-hours: Oct 17, 2025, 7:55 PM EDT
EyePoint Pharmaceuticals Revenue
EyePoint Pharmaceuticals had revenue of $5.33M in the quarter ending June 30, 2025, a decrease of -43.73%. This brings the company's revenue in the last twelve months to $51.90M, up 2.99% year-over-year. In the year 2024, EyePoint Pharmaceuticals had annual revenue of $43.27M, down -5.97%.
Revenue (ttm)
$51.90M
Revenue Growth
+2.99%
P/S Ratio
14.50
Revenue / Employee
$314,533
Employees
165
Market Cap
801.63M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 43.27M | -2.75M | -5.97% |
Dec 31, 2023 | 46.02M | 4.61M | 11.14% |
Dec 31, 2022 | 41.40M | 4.47M | 12.09% |
Dec 31, 2021 | 36.94M | 2.50M | 7.27% |
Dec 31, 2020 | 34.44M | 14.07M | 69.10% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
EYPT News
- 3 days ago - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 days ago - EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study - Benzinga
- 4 days ago - EyePoint Announces Pricing of Public Offering - GlobeNewsWire
- 5 days ago - EyePoint Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 5 days ago - EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema - GlobeNewsWire
- 6 weeks ago - EyePoint Pharmaceuticals, Inc. (EYPT) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 7 weeks ago - EyePoint Announces Participation at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - EyePoint Pharmaceuticals, Inc. (EYPT) Q2 2025 Earnings Call Transcript - Seeking Alpha